Resultado de búsqueda
22 de may. de 2024 · May 22, 2024. Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024. – Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease –.
Hace 17 horas · FOSTER CITY, Calif. & HAYWARD, Calif., June 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 ...
22 de may. de 2024 · FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress,...
Hace 5 días · Tue, May 28, 2024, 7:00 AM 2 min read. In this article: GILD. – Collaboration utilizes Cartography’s ATLAS and SUMMIT Platforms to discover targets in triple-negative breast cancer and lung...
Hace 4 días · Patrick Ingiliz has received research grants from Gilead Sciences (Noco and HDV Described) and Abbott Laboratories and speaker's honoraria from Gilead Sciences, ViiV Healthcare, and AbbVie. Stefan Christensen has received personal fees and travel grants from Gilead Sciences, AbbVie, and ViiV Healthcare outside the submitted work.
7 de may. de 2024 · May 07, 2024. Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024. – Non-Small Cell Lung Cancer Development Program Data to be Presented, Including the Phase 3 EVOKE-01 Study –. – Updated Results from Phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab, to be Presented –.
Hace 4 días · Gilead’s growing oncology portfolio and its efforts to expand global access to treatment attracted Luciana Preger to join the company. Read more.
